Abstracts tagged "Biomarkers"

Abstract Number: 869 • 2016 ACR/ARHP Annual Meeting
Low Numbers of CD16+ Monocytes Predict Shorter Time to Relapse in Polymyalgia Rheumatica
Qi Wang¹, Kornelis S.M. van der Geest², Wayel H. Abdulahad¹, Abraham Rutgers¹, Suzanne Arends¹, Annemieke M.H. Boots¹ and Elisabeth Brouwer³, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) is the most frequent inflammatory disorder in persons older than 50 years of age. Biomarkers like ESR and CRP may be…
Abstract Number: 1638 • 2016 ACR/ARHP Annual Meeting
Antibody Mediated Immunity Drives Response to Methotrexate Treatment in Rheumatoid Arthritis Patients
Boel Brynedal¹, Helga Westerlind², Lasse Folkersen^3,4, Leonid Padyukov⁵, Nancy Vivar⁵, Anca I Catrina⁶, Lars Klareskog⁵ and Louise Berg⁵, ¹Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska, Sweden, ²Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark, ⁵Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Methotrexate (MTX) is the first line treatment for Rheumatoid Arthritis (RA) in Sweden, but one third of patients do not experience satisfying treatment response.…
Abstract Number: 2135 • 2016 ACR/ARHP Annual Meeting
Knee Osteoarthritis Pain Is Differentially Associated with Tissue Degradation and Joint Inflammation
Anne C. Bay-Jensen¹, Steven B. Abramson², Jonathan Samuels³, Inger Byrjalsen⁴, Svetlana Krasnokutsky Samuels⁵, Tina Manon-Jensen⁶, Morten Asser Karsdal¹ and Mukundan Attur⁷, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Rheumatology Research, NYU School of Medicine and NYU Hospital for Joint Diseases, New York, NY, ³Department of Medicine, NYU School of Medicine, NYU Langone Medical Center, New York, NY, ⁴Nordic Bioscience, Clinical Development, Herlev, Denmark, ⁵Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, ⁶Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁷Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY
Background/Purpose: Osteoarthritis (OA) is a disease characterized by pain and tissue destruction, in some cases concomitant with inflammation. The link between pain and tissue destruction…
Abstract Number: 2587 • 2016 ACR/ARHP Annual Meeting
The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Arata Nakajima¹, Keiichiro Yamamoto² and Koichi Nakagawa³, ¹Orthopaedics, Toho University Sakura Medical Center, Sakura, Japan, ²Orthopedics, Toho University Sakura Medical Center, Sakura, Japan, ³Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 3035 • 2016 ACR/ARHP Annual Meeting
Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease
Yahui Grace Chiu¹, Edward Schwarz², Richard Bell³, Dongge Li⁴, Nelson Huertas⁴, Cristy Bell⁵, Sharon Moorehead⁵, Debbie Campbell⁵, Changyong Feng⁶ and Christopher T. Ritchlin⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Orthopedeatrics, University of Rochester, Rochester, NY, ³Pathology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁶Statistics, University of Rochester, Rochester, NY, ⁷Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease that affects over 650,000 Americans. Bone damage occurs in half of these patients within the first…
Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Jeffrey R. Curtis¹, Jeffrey D. Greenberg², Leslie Harrold³ and J. Lynn Palmer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona, LLC, Southborough, MA, ³Department of Medicine, UMass Memorial Medical Center, Worcester, MA, ⁴Corrona Research Foundation, Albany, NY
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…
Abstract Number: 770 • 2015 ACR/ARHP Annual Meeting
Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study
Alfred Kim¹, Vibeke Strand², Nancy Mathis¹, Deepali Sen³, Jonathan Miner³, Elizabeth Schramm¹, Robin Bruchas⁴, Nick Staten⁴, Paul Olson⁴, Chad Stiening⁴ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO, ⁴Kypha, Inc., Saint Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 1243 • 2015 ACR/ARHP Annual Meeting
Identification of the Gene Expression Signatures Predicting the Responses to Three Biologics (infliximab, tocilizumab, and abatacept) in Rheumatoid Arthritis
Seiji Nakamura¹, Hiroshi Iijima¹, Yuko Hata², Yohei Ishizawa², Chun Ren Lim², Ryo Matoba², Katsuya Suzuki³, Koichi Amano⁴ and Tsutomu Takeuchi³, ¹Kanagawa, DNA Chip Research Inc., Yokohama, Japan, ²DNA Chip Research Inc., Yokohama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Background/Purpose: Employing genome-wide gene transcription on a unified platform, to identify molecular signatures for predicting therapeutic effects for rheumatoid arthritis (RA) with three biologics, infliximab…
Abstract Number: 1742 • 2015 ACR/ARHP Annual Meeting
Fingerprint Biomarkers of Type I and III Collagen in Axial Spondyloarthropathy (axSpA) and Psoriatic Arthritis (PsA). Association with Disease Activity and Diagnostic Capacity
Natasja Stæhr Gudman¹, Anne Friesgaard Christensen², Grith Lykke Sørensen³, Anne C. Bay-Jensen⁴, Anne Sofie Siebuhr⁵, Morten Asser Karsdal⁶, Heidi Lausten Munk⁷, Leif Ejstrup⁸, Anne Gitte Loft⁹ and Peter Junker¹⁰, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Rheumatology, Odense University Hospital, Odense, Denmark, ³Cardiovascular and Renal Research, Institute of Molecular Medicin, University of Southern Denmark, Odense, Denmark, ⁴Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁶Research & Development, Nordic Bioscience, Herlev, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁸Odense University Hosp, SDR Blvd, Odense, Denmark, ⁹Department of Rheumatology, Vejle Hospital, Vejle, Denmark, ¹⁰University of Southern Denmark, Odense, Denmark
Background/Purpose: AxSpA and PsA are core members of the spondyloarthritis complex. One cardinal characteristic shared by these two conditions is increased remodeling of bone and…
Abstract Number: 2066 • 2015 ACR/ARHP Annual Meeting
Elevated Innate, Adaptive, and TNF-Superfamily Soluble Inflammatory Mediators Mark Impending Disease Flare, While Regulatory Mediators Distinguish Lack of Impending Disease Flare in African-American SLE Patients with Active Disease
Melissa E. Munroe¹, Evan G. Vista², Joan T. Merrill³, Joel M. Guthridge¹, Virginia C. Roberts¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a multifaceted disease characterized by immune dysregulation and varied disease activity. Identifying mechanistic mediators of altered disease activity would help prevent damage…
Abstract Number: 2694 • 2015 ACR/ARHP Annual Meeting
Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis
Zuzana Tatar¹, Carole Migne², Mélanie Petera³, Estelle Pujos Guillot⁴, Philippe Gaudin^5,6, T Lequerré⁷, Hubert Marotte⁸, Jacques Tebib⁹ and Martin Soubrier¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Metabolomic Plateform INRA, Theix-Clermont-Ferrand, France, ³Metabolomic Plateform, INRA, Theix -Clermont-Ferrand, France, ⁴Metabolomic Plateform, INRA, Theix-Clermont-Ferrand, France, ⁵Rheumatology, University Hospital, Grenoble, France, ⁶Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁷Rheumatology Department and INSERM U 905, CHU Hôpitaux de Rouen, Rouen, France, ⁸INSERM 1059 / LBTO, Université de Lyon, Saint-Etienne; Rheumatology Department, Saint-Etienne, France, ⁹Rheumatology Department, Centre Hospitalier Lyon-Sud, Pierre-Bénite Lyon, France
Background/Purpose: Anti-TNF-alpha therapies are able to control rheumatoid arthritis (RA) disease activity and to limit structural damage. Nevertheless, no predictive factor of response to anti-TNF-alpha,…
Abstract Number: 3115 • 2015 ACR/ARHP Annual Meeting
Autoantibodies of the IgA Type a Link Between the Gut and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Clinical Trials
Zoltan Konthur¹, Ute Nonhof², Melvin Michael Wiemkes³, Jacqueline Detert³, Tanja Braun⁴, Jörg Hollidt², Gerd Burmester⁵ and Karl Skriner⁵, ¹Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany, ²Drug Response DX GmbH, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: So far no mechanism for non response to biologicals targeting TNFα has been described despite one third of rheumatoid arthritis patients treated are non-responders.…
Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
KAZUYUKI YOSHIZAKI, Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Suita, Japan
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…
Abstract Number: 772 • 2015 ACR/ARHP Annual Meeting
Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays
John Conklin¹, Basil Jones², Tyler O'Malley³, Duncan Poling⁴, JoAnne Ligayon⁵, Leilani Wolover⁶, Ying Qu⁷, Claudia Ibarra⁸, Puja Chitkara⁹ and Thierry Dervieux³, ¹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²Exagen Diagnostics, Vista, CA, ³Research and Development, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics Inc., Vista, CA, ⁵Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷Exagen Diagnostic Inc, Vista, CA, ⁸Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA
Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed…
Abstract Number: 1259 • 2015 ACR/ARHP Annual Meeting
Verification of Haptoglobin and Von Willebrand Factor As Potential Biomarkers of Knee Osteoarthritis Using a Targeted Proteomics Approach in Serum
Patricia Fernandez-Puente¹, Valentina Calamia¹, Jesús Mateos¹, Lucia Lourido¹, Beatriz Rocha², Cristina Ruiz-Romero¹ and Francisco J. Blanco¹, ¹Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ²Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain
Background/Purpose: The current diagnosis of osteoarthritis (OA) relies on the description of pain symptoms, affected joint stiffness, and radiography used as the reference technique…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].